Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome

Over 80% of assessed basal cell carcinoma lesions regressed across three Gorlin syndrome patients treated with KB113 Substantial regression was observed in lesions not directly injected with KB113, consistent with abscopal effect KB113 injections were well tolerated by Gorlin syndrome patients; all reported adverse events were mild to moderate in severity and transient in nature Data will be presented by study investigator Dr. Shireen Guide at the 14th PeDRA Annual Conference, October 15-17, 202